

Gibson Dunn Advises XOMA Royalty on Sale to Ligand Pharmaceuticals

Firm News | April 28, 2026

Gibson Dunn is advising XOMA Royalty on its sale to Ligand Pharmaceuticals Inc.

The firm's corporate team is led by partners Ryan Murr and Branden Berns and includes associate Evan Shepherd. Partners Pamela Lawrence Endreny and Rachel Kleinberg are advising on tax aspects. Partner Sean Feller is advising on benefits.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Evan Shepherd](#)

[Pamela Lawrence Endreny](#)

[Rachel D. Kleinberg](#)

[Sean C. Feller](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)